JPMorgan BetaBuilders Europe ETF
J.P. Morgan Exchange-Traded Fund Trust · 1 share class
Fund classification
Classified from what the fund holds · as of 2026 Q2
JPMorgan BetaBuilders Europe ETF is a developed international equity index ETF that tracks the Morningstar Developed Europe Target Market Exposure Index.
- Asset class
- Equity
- Region
- Developed international
- Management
- Index (passive)
- Fund type
- ETF
- Features
- Non-diversified
Fund profile
As filed in the prospectus · 2026 Q1
The Fund seeks investment results that closely correspond, before fees and expenses, to the performance of the Morningstar Developed Europe Target Market Exposure Index SM .
The fund employs a passive indexing strategy to track the Morningstar Developed Europe Target Market Exposure Index, a market-capitalization-weighted index of large- and mid-cap equities from 16 developed European countries. The fund invests at least 80% of assets in index constituents and may use representative sampling rather than holding all securities, which could cause tracking divergence from the index. The fund may operate as non-diversified to the extent the underlying index is non-diversified, and concentrations in particular issuers or industries will reflect index weightings.
| Share class | Expense ratio |
|---|---|
| BBEU | 0.09% |
Portfolio turnover 5.00% · as of 2026 Q1
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 99.12% |
| Cash & short-term | 5.03% |
| Derivatives | 0.03% |
Derivatives are shown at market value, not notional exposure.
Latest quarter
What changed since the fund's previous filing
Largest new: Roche Holding AG, Reckitt Benckiser Group plc, CSG NV
Largest exited: Roche Holding AG, Reckitt Benckiser Group plc, Ashtead Group plc, JDE Peet's NV
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| — | ASML Holding NV | 4.15% | $1,445.55 | $372.89M | 258.0K |
| — | JPMorgan Securities Lending Money Market Fund | 4.12% | — | $369.90M | — |
| — | HSBC Holdings plc | 2.34% | $18.40 | $210.24M | 11.4M |
| — | AstraZeneca plc | 2.18% | $189.72 | $195.42M | 1.0M |
| — | Novartis AG | 2.09% | $147.79 | $187.23M | 1.3M |
| — | Roche Holding AG | 2.08% | $407.50 | $186.89M | 458.6K |
| — | Nestle SA | 1.93% | $101.24 | $172.83M | 1.7M |
| — | Shell plc | 1.90% | $45.47 | $170.92M | 3.8M |
| — | Siemens AG | 1.61% | $297.16 | $144.69M | 486.9K |
| — | TotalEnergies SE | 1.35% | $92.97 | $121.13M | 1.3M |
Reported price is the fund's own reported value divided by its own reported shares at 2026-04-30 — not a live quote, and not what the fund paid.
Top 10 positions are 23.75% of net assets, top 25 40.10%, across 353 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free